Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

Fig. 1

Adjusted hazard ratios (95% confidence intervals) of outcomes among anticoagulant users, stratified by subgroups, MarketScan, 2010–2014. Panel a: New rivaroxaban users vs. new warfarin users. Panel b: Patients who switched from warfarin to rivaroxaban vs. persistent warfarin users. Panel c: New rivaroxaban users vs. new dabigatran users

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us